2017-02-10 CSRO Supports Biosimilars
back to news
CSRO Supports Biosimilars Legislation in Multiple States this Week
Posted: February 10, 2017
Legislation is being unveiled across the country to address Biosimilars, and create the pathways needed for pharmacists to dispense Biosimilar substitutions to patients, while communicating the substitution with the patient’s physician in a timely manner (which currently is 3 to 5 days for all bills listed).
- In Montana this week, CSRO is happy to report that HB233 was transferred through the House, passed Senate Committee, and awaits action on the Senate Floor.
- In Alaska the Senate Health and Human Services Committee is hearing SB32 on Friday, February 10.
- In Arkansas the Public Health, Welfare and Labor Committee heard HB1204 on Thursday, February 9.
- In Iowa, a Senate Human Resources Subcommittee will hear Study Bill 1029 on Thursday, February 9, and the House Human Resources Committee contains Study Bill 38.
- In Kansas HB2107 passed through the House Health and Human Services Committee thanks in part to the terrific advocacy provided by Dr. Mark Box.
- In Minnesota HF712 awaits a hearing from the House Health and Human Resources Committee.
- In New Mexico HB260 is being heard in the House Health and Human Services Committee on Friday, February 10, and the Senate Public Affairs Committee will hear a similar bill, SB180, that same day.
- In Nebraska LB481 passed through the Health and Human Services Committee, and awaits Floor Action.
- In South Carolina HB3438 awaits a hearing from the House Committee on Medical, Military, Public and Municipal Affairs.
- In Wyoming SF121 awaits a hearing from the House Corporations Committee.
The CSRO would like to thank all of the legislators and advocates that helped these states move toward joining the 26 others that have enacted laws to protect their patients, and provide the passages necessary to gain access to unique Biosimilars. The CSRO and its Government Affairs team will continue to track these bills through their respective State processes. Please check the website for further updates on Biosimilar legislation.